nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.756	1	CbGaD
Dextroamphetamine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.014	0.212	CbGeAlD
Dextroamphetamine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00744	0.112	CbGeAlD
Dextroamphetamine—TAAR1—nervous system—attention deficit hyperactivity disorder	0.00454	0.0686	CbGeAlD
Dextroamphetamine—TAAR1—central nervous system—attention deficit hyperactivity disorder	0.00437	0.0661	CbGeAlD
Dextroamphetamine—SLC18A2—forebrain—attention deficit hyperactivity disorder	0.00284	0.043	CbGeAlD
Dextroamphetamine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00215	0.0325	CbGeAlD
Dextroamphetamine—SLC18A2—midbrain—attention deficit hyperactivity disorder	0.00187	0.0284	CbGeAlD
Dextroamphetamine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00173	0.0262	CbGeAlD
Dextroamphetamine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00161	0.0244	CbGeAlD
Dextroamphetamine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.00156	0.0235	CbGeAlD
Dextroamphetamine—SLC18A2—nervous system—attention deficit hyperactivity disorder	0.00154	0.0233	CbGeAlD
Dextroamphetamine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.0015	0.0227	CbGeAlD
Dextroamphetamine—SLC18A2—central nervous system—attention deficit hyperactivity disorder	0.00148	0.0225	CbGeAlD
Dextroamphetamine—SLC18A2—cerebellum—attention deficit hyperactivity disorder	0.00145	0.0219	CbGeAlD
Dextroamphetamine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.00142	0.0215	CbGeAlD
Dextroamphetamine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.00136	0.0206	CbGeAlD
Dextroamphetamine—ADRA1B—brain—attention deficit hyperactivity disorder	0.00119	0.018	CbGeAlD
Dextroamphetamine—SLC18A2—brain—attention deficit hyperactivity disorder	0.00118	0.0178	CbGeAlD
Dextroamphetamine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.00117	0.0176	CbGeAlD
Dextroamphetamine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.00112	0.017	CbGeAlD
Dextroamphetamine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.0011	0.0166	CbGeAlD
Dextroamphetamine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000949	0.0144	CbGeAlD
Dextroamphetamine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000941	0.0142	CbGeAlD
Dextroamphetamine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000906	0.0137	CbGeAlD
Dextroamphetamine—SLC6A3—brain—attention deficit hyperactivity disorder	0.000891	0.0135	CbGeAlD
Dextroamphetamine—Tolazoline—ADRA2C—attention deficit hyperactivity disorder	0.000884	0.0908	CrCbGaD
Dextroamphetamine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000874	0.0132	CbGeAlD
Dextroamphetamine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000842	0.0127	CbGeAlD
Dextroamphetamine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000823	0.0124	CbGeAlD
Dextroamphetamine—SLC6A2—brain—attention deficit hyperactivity disorder	0.000719	0.0109	CbGeAlD
Dextroamphetamine—ADRA1A—brain—attention deficit hyperactivity disorder	0.000668	0.0101	CbGeAlD
Dextroamphetamine—Pargyline—MAOA—attention deficit hyperactivity disorder	0.000644	0.0661	CrCbGaD
Dextroamphetamine—Diethylpropion—SLC6A3—attention deficit hyperactivity disorder	0.000632	0.0649	CrCbGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000543	0.00324	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000534	0.00318	CbGpPWpGaD
Dextroamphetamine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000515	0.00779	CbGeAlD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.000514	0.00306	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000506	0.00302	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000506	0.00301	CbGpPWpGaD
Dextroamphetamine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000496	0.0075	CbGeAlD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.000493	0.00294	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—ADRA2C—attention deficit hyperactivity disorder	0.000491	0.0504	CrCbGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00049	0.00292	CbGpPWpGaD
Dextroamphetamine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000485	0.00733	CbGeAlD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000482	0.00287	CbGpPWpGaD
Dextroamphetamine—Lisdexamfetamine—SLC6A3—attention deficit hyperactivity disorder	0.000479	0.0492	CrCbGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000476	0.00283	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000475	0.00283	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000474	0.00283	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000443	0.00264	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000441	0.00263	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.000436	0.0026	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000422	0.00251	CbGpPWpGaD
Dextroamphetamine—Tranylcypromine—MAOA—attention deficit hyperactivity disorder	0.000415	0.0426	CrCbGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000414	0.00247	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000399	0.00238	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000394	0.00235	CbGpPWpGaD
Dextroamphetamine—CYP2D6—brain—attention deficit hyperactivity disorder	0.000394	0.00596	CbGeAlD
Dextroamphetamine—SLC6A3—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.000394	0.00235	CbGpPWpGaD
Dextroamphetamine—Phenylpropanolamine—MAOA—attention deficit hyperactivity disorder	0.00039	0.0401	CrCbGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000386	0.0023	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000385	0.0023	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000379	0.00226	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000377	0.00225	CbGpPWpGaD
Dextroamphetamine—Tolazoline—ADRA2A—attention deficit hyperactivity disorder	0.000377	0.0387	CrCbGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000373	0.00222	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000372	0.00222	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000367	0.00219	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000362	0.00216	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000358	0.00214	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000355	0.00212	CbGpPWpGaD
Dextroamphetamine—Phenylpropanolamine—DRD1—attention deficit hyperactivity disorder	0.000355	0.0364	CrCbGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000354	0.00211	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000353	0.0021	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000351	0.00209	CbGpPWpGaD
Dextroamphetamine—Phentermine—MAOA—attention deficit hyperactivity disorder	0.000348	0.0357	CrCbGaD
Dextroamphetamine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000347	0.00207	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000338	0.00201	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000337	0.00201	CbGpPWpGaD
Dextroamphetamine—Phenylpropanolamine—SLC6A3—attention deficit hyperactivity disorder	0.000336	0.0345	CrCbGaD
Dextroamphetamine—Phenylpropanolamine—ADRA2A—attention deficit hyperactivity disorder	0.00033	0.0339	CrCbGaD
Dextroamphetamine—Pseudoephedrine—MAOA—attention deficit hyperactivity disorder	0.00033	0.0338	CrCbGaD
Dextroamphetamine—Selegiline—MAOA—attention deficit hyperactivity disorder	0.000322	0.033	CrCbGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000316	0.00188	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000314	0.00187	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00031	0.00185	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.000305	0.00182	CbGpPWpGaD
Dextroamphetamine—Phentermine—SLC6A3—attention deficit hyperactivity disorder	0.0003	0.0308	CrCbGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000291	0.00173	CbGpPWpGaD
Dextroamphetamine—Pseudoephedrine—SLC6A3—attention deficit hyperactivity disorder	0.000284	0.0292	CrCbGaD
Dextroamphetamine—Phenelzine—MAOA—attention deficit hyperactivity disorder	0.000283	0.0291	CrCbGaD
Dextroamphetamine—Pseudoephedrine—ADRA2A—attention deficit hyperactivity disorder	0.000279	0.0286	CrCbGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000272	0.00162	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000271	0.00161	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00027	0.00161	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00027	0.00161	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000268	0.0016	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000267	0.00159	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000265	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000265	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.000265	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000263	0.00157	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000263	0.00157	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000255	0.00152	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00025	0.00149	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—MAOA—attention deficit hyperactivity disorder	0.000248	0.0254	CrCbGaD
Dextroamphetamine—TAAR1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000246	0.00147	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000243	0.00145	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000241	0.00144	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00024	0.00143	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000239	0.00142	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000236	0.00141	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000236	0.0014	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.000235	0.0014	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000234	0.0014	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000234	0.00139	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000232	0.00138	CbGpPWpGaD
Dextroamphetamine—Amphetamine—SLC6A3—attention deficit hyperactivity disorder	0.00023	0.0237	CrCbGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000227	0.00135	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000226	0.00135	CbGpPWpGaD
Dextroamphetamine—Phentermine—SLC6A4—attention deficit hyperactivity disorder	0.000224	0.023	CrCbGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000222	0.00132	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000218	0.0013	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000214	0.0219	CrCbGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000213	0.00127	CbGpPWpGaD
Dextroamphetamine—Pseudoephedrine—SLC6A4—attention deficit hyperactivity disorder	0.000212	0.0218	CrCbGaD
Dextroamphetamine—Benzphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000212	0.0218	CrCbGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000212	0.00126	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000212	0.00126	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000211	0.00126	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00021	0.00125	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—ADRA2A—attention deficit hyperactivity disorder	0.000209	0.0215	CrCbGaD
Dextroamphetamine—Benzphetamine—ADRA2A—attention deficit hyperactivity disorder	0.000208	0.0213	CrCbGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000207	0.00124	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000207	0.00124	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000206	0.00123	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000205	0.00122	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000205	0.00122	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000203	0.00121	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000203	0.00121	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000202	0.0012	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000201	0.0012	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000198	0.00118	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000191	0.00114	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000191	0.00114	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000188	0.00112	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000186	0.00111	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000184	0.0011	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000177	0.00105	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000173	0.00103	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000173	0.00103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000173	0.00103	CbGpPWpGaD
Dextroamphetamine—Amphetamine—SLC6A4—attention deficit hyperactivity disorder	0.000172	0.0177	CrCbGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000171	0.00102	CbGpPWpGaD
Dextroamphetamine—Amphetamine—DRD2—attention deficit hyperactivity disorder	0.000171	0.0176	CrCbGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000163	0.000973	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000161	0.00096	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000161	0.000957	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—SLC6A4—attention deficit hyperactivity disorder	0.00016	0.0164	CrCbGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000159	0.00095	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000158	0.000943	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000157	0.000939	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000157	0.000938	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000157	0.000935	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000154	0.000916	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000149	0.00089	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000149	0.000887	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000145	0.000862	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000144	0.000857	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000143	0.00085	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000142	0.000847	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00014	0.000837	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00014	0.000834	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000138	0.00082	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000135	0.000805	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000134	0.000796	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000133	0.000791	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000132	0.000788	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000131	0.00078	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000129	0.000772	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000128	0.000766	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000128	0.000763	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000126	0.000753	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000126	0.000749	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000125	0.000743	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000124	0.000739	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000122	0.000729	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000122	0.000728	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.000726	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000121	0.000723	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000121	0.000722	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00012	0.000717	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00012	0.000715	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00012	0.000715	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000119	0.000706	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000117	0.000696	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000116	0.000693	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000114	0.000677	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000113	0.000674	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000112	0.000668	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000111	0.000663	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00011	0.000656	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00011	0.000654	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000108	0.000645	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000107	0.000637	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000107	0.000635	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000106	0.000632	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000105	0.000627	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000105	0.000625	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000102	0.00061	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	9.98e-05	0.000595	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	9.95e-05	0.000593	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	9.78e-05	0.000583	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	9.74e-05	0.000581	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	9.44e-05	0.000562	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	9.42e-05	0.000561	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.31e-05	0.000555	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	9.28e-05	0.000553	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.16e-05	0.000546	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.16e-05	0.000546	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.06e-05	0.00054	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.88e-05	0.000529	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	8.86e-05	0.000528	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	8.71e-05	0.000519	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.68e-05	0.000518	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.65e-05	0.000516	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	8.53e-05	0.000509	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	8.42e-05	0.000502	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.38e-05	0.0005	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	8.36e-05	0.000498	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	8.3e-05	0.000495	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.24e-05	0.000491	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.14e-05	0.000485	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.14e-05	0.000485	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	8.05e-05	0.00048	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.98e-05	0.000476	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.89e-05	0.00047	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.85e-05	0.000468	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.58e-05	0.000452	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.16e-05	0.000427	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.09e-05	0.000423	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.97e-05	0.000416	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.78e-05	0.000404	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.23e-05	0.000371	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.15e-05	0.000367	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.02e-05	0.000359	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.98e-05	0.000356	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.92e-05	0.000353	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.53e-05	0.00033	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.51e-05	0.000328	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.47e-05	0.000326	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.38e-05	0.000321	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.35e-05	0.000319	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.33e-05	0.000318	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.31e-05	0.000316	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.26e-05	0.000314	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.24e-05	0.000313	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.24e-05	0.000312	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.18e-05	0.000309	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.14e-05	0.000307	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5e-05	0.000298	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.89e-05	0.000292	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.84e-05	0.000289	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.82e-05	0.000287	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.78e-05	0.000285	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.76e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.75e-05	0.000283	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.74e-05	0.000282	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.7e-05	0.00028	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.66e-05	0.000278	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.66e-05	0.000278	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.6e-05	0.000274	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.57e-05	0.000272	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.44e-05	0.000265	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.38e-05	0.000261	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.3e-05	0.000256	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.28e-05	0.000255	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.23e-05	0.000252	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.18e-05	0.000249	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.89e-05	0.000232	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.79e-05	0.000226	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.64e-05	0.000217	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.44e-05	0.000205	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.38e-05	0.000201	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.23e-05	0.000192	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.18e-05	0.000189	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.07e-05	0.000183	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3e-05	0.000179	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.95e-05	0.000176	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.86e-05	0.000171	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.82e-05	0.000168	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.81e-05	0.000168	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.78e-05	0.000166	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.72e-05	0.000162	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.62e-05	0.000156	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.59e-05	0.000154	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.54e-05	0.000151	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.5e-05	0.000149	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.47e-05	0.000147	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.38e-05	0.000142	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.38e-05	0.000142	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.34e-05	0.000139	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.3e-05	0.000137	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.17e-05	0.00013	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.9e-05	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.81e-05	0.000108	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.81e-05	0.000108	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.61e-05	9.59e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.44e-05	8.58e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.43e-05	8.52e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.6e-06	5.72e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.53e-06	5.08e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	6.17e-06	3.68e-05	CbGpPWpGaD
